Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 2, 2006, Pages 592-600

  Bergheim, Ina ^a   Guo, Luping ^a   Davis, Molly Anne ^a   Duveau, Ilinca ^a   Arteel, Gavin E ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; COLLAGEN; HYDROXYPROLINE; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SCATTER FACTOR RECEPTOR; UROKINASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; INTRAHEPATIC CHOLESTASIS; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER INJURY; MEDICAL ASSESSMENT; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; SPECIES COMPARISON; STELLATE CELL; TISSUE SECTION;

ANIMALS; CHOLESTASIS; DISEASE MODELS, ANIMAL; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 31144453564     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.095042     Document Type: Article

References (40)

1. Arndt PG, Young SK, and Worthen GS (2005) Regulation of lipopolysaccharideinduced lung inflammation by plasminogen activator inhibitor-1 through a JNKmediated pathway. J Immunol 175:4049-4059.
2. Arteel GE, Iimuro Y, Yin M, Raleigh JA, and Thurman RG (1997) Chronic enteral ethanol treatment causes hypoxia in rat liver tissue in vivo. Hepatology 25:920-926.
3. Arthur MJ (2000) Fibrogenesis: II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol 279:G245-G249.
4. Bataller R and Brenner DA (2005) Liver fibrosis. J Clin Investig 115:209-218.
5. Bezerra JA, Currier AR, Melin-Aldana H, Sabla G, Bugge TH, Kombrinck KW, and Degen JL (2001) Plasminogen activators direct reorganization of the liver lobule after acute injury. Am J Pathol 158:921-929.
6. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, and Aaronson SA (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (Wash DC) 251:802-804.
7. Bueno MR, Daneri A, and Armendariz-Borunda J (2000) Cholestasis-induced fibrosis is reduced by interferon alpha-2a and is associated with elevated liver metalloprotease activity. J Hepatol 33:915-925.
8. Canbay A, Guicciardi ME, Higuchi H, Feldstein A, Bronk SF, Rydzewski R, Taniai M, and Gores GJ (2003) Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Investig 112:152-159.
9. Ellis AJ, Curry VA, Powell EK, and Cawston TE (1994) The prevention of collagen breakdown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor. Biochem Biophys Res Commun 201:94-101.
10. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, Trozzi L, Surrenti C, and Casini A (2002) Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122:1924-1940.
11. Gujral JS, Farhood A, Bajt ML, and Jaeschke H (2003) Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct-ligated mice. Hepatology 38:355-363.
12. Gujral JS, Liu J, Farhood A, Hinson JA, and Jaeschke H (2004a) Functional importance of ICAM-1 in the mechanism of neutrophil-induced liver injury in bile duct-ligated mice. Am J Physiol 286:G499-G507.
13. Gujral JS, Liu J, Farhood A, and Jaeschke H (2004b) Reduced oncotic necrosis in Fas receptor-deficient C57BL/6J-lpr mice after bile duct ligation. Hepatology 40:998-1007.
14. Guo L, Richardson KS, Tucker LM, Doll MA, Hein DW, and Arteel GE (2004) Role of the renin-angiotensin system in hepatic ischemia reperfusion injury in rats. Hepatology 40:583-589.
15. Hattori N, Degen JL, Sisson TH, Liu H, Moore BB, Pandrangi RG, Simon RH, and Drew AF (2000) Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Investig 106:1341-1350.
16. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, and Noble NA (2003) A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Investig 112:379-388.
17. Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, and Vaughan DE (2001) Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 104:839-844.
18. Kim WR, Brown RS Jr, Terrault NA, and El Serag H (2002) Burden of liver disease in the United States: summary of a workshop. Hepatology 36:227-242.
19. Kruithof EK (1988) Plasminogen activator inhibitors: a review. Enzyme 40:113-121.
20. Lagoa CE, Vodovotz Y, Stolz DB, Lhuillier F, McCloskey C, Gallo D, Yang R, Ustinova E, Fink MP, Billiar TR, et al. (2005) The role of hepatic type 1 plasminogen activator inhibitor (PAI-1) during murine hemorrhagic shock. Hepatology 42:390-399.
21. Leyland H, Gentry J, Arthur MJ, and Benyon RC (1996) The plasminogen-activating system in hepatic stellate cells. Hepatology 24:1172-1178.
22. Lin Y, Xie WF, Chen YX, Zhang X, Zeng X, Qiang H, Chen WZ, Yang XJ, Han ZG, and Zhang ZB (2005) Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes. Liver Int 25:796-807.
23. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, and Garbisa S (1981) Effect of plasminogen activator (urokinase), plasmin and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41:4629-4636.
24. Lopez-De Leon A and Rojkind M (1985) A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 33:737-743.
25. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, and Mallat A (2005) Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 45:605-628.
26. Luyendyk JP, Maddox JF, Green CD, Ganey PE, and Roth RA (2004) Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide- ranitidine coexposure in rats. Hepatology 40:1342-1351.
27. Mackay AR, Corbitt RH, Hartzler JL, and Thorgeirsson UP (1990) Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 50:5997-6001.
28. Marshall LJ, Ramdin LS, Brooks T, DPhil PC, and Shute JK (2003) Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/ syndecan-1 complexes. J Immunol 171:2057-2065.
29. Mochan E and Keler T (1984) Plasmin degradation of cartilage proteoglycan. Biochim Biophys Acta 800:312-315.
30. Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, and Comoglio PM (1995) Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 270:603-611.
31. Ng VL, Sabla GE, Melin-Aldana H, Kelley-Loughnane N, Degen JL, and Bezerra JA (2001) Plasminogen deficiency results in poor clearance of non-fibrin matrix and persistent activation of hepatic stellate cells after an acute injury. J Hepatol 35:781-789.
32. Parsons CJ, Bradford BU, Pan CQ, Cheung E, Schauer M, Knorr A, Krebs B, Kraft S, Zahn S, Brocks B, et al. (2004) Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology 40:1106-1115.
33. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, and Albrecht J (2002) Impact of pegylated interferon α-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122:1303-1313.
34. Quax PH, van den Hoogen CM, Verheijen JH, Padro T, Zeheb R, Gelehrter TD, van Berkel TJ, Kuiper J, and Emeis JJ (1990) Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem 265:15560-15563.
35. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, and Quigley JP (1999) Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274: 13066-13076.
36. Salgado S, Garcia J, Vera J, Siller F, Bueno M, Miranda A, Segura A, Grijalva G, Segura J, Orozco H, et al. (2000) Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2:545-551.
37. Taniyama Y, Morishita R, Nakagami H, Moriguchi A, Sakonjo H, Shokei K, Matsumoto K, Nakamura T, Higaki J, and Ogihara T (2000) Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 102: 246-252.
38. Toschi V, Rocchini GM, Motta A, Fiorini GF, Cimminiello C, Violi F, Castelli C, Sironi D, and Gibelli A (1993) The hyperfibrinolytic state of liver cirrhosis: possible pathogenetic role of ascites. Biomed Pharmacother 47:345-352.
39. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, Matsumoto K, Nakamura T, Takahashi H, Okamoto E, et al. (1999) Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 5:226-230.
40. Zhang LP, Takahara T, Yata Y, Furui K, Jin B, Kawada N, and Watanabe A (1999) Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. J Hepatol 31:703-711.